Camizestrant Combination Reduced Risk of First and Second Disease Progression in ESR1-Mutant Advanced HR-Positive Breast Cancer in SERENA-6
AstraZeneca has announced updated positive findings from its pivotal Phase III SERENA-6 clinical trial, reinforcing the potential of camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor as a transformative treatment strategy for patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer. The latest data, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, demonstrate that the camizestrant-based regimen not only maintains its previously reported progression-free survival (PFS) advantage but also delivers significant benefits beyond initial treatment, including improved second progression-free survival (PFS2), substantial reductions in circulating tumor DNA (ctDNA), and delayed need for more intensive therapies.
The findings further strengthen the growing evidence supporting a proactive treatment-switch strategy when ESR1 mutations emerge during first-line therapy. Researchers believe the results could reshape the standard approach to managing HR-positive, HER2-negative advanced breast cancer by introducing earlier intervention before disease progression occurs.
Building on Earlier Success
The SERENA-6 study was designed to evaluate whether patients with HR-positive, HER2-negative advanced breast cancer would benefit from switching to camizestrant plus a CDK4/6 inhibitor immediately after detection of an ESR1 mutation, rather than remaining on standard endocrine therapy consisting of an aromatase inhibitor (AI) and a CDK4/6 inhibitor.
Patients enrolled in the trial were initially receiving first-line treatment with either anastrozole or letrozole in combination with one of three commonly used CDK4/6 inhibitors: palbociclib, ribociclib, or abemaciclib. Once an ESR1 mutation was detected through molecular monitoring, patients were randomized either to switch to camizestrant while continuing their CDK4/6 inhibitor or to remain on their existing aromatase inhibitor-based regimen.
The trial previously achieved its primary endpoint at an interim analysis, demonstrating a significant progression-free survival benefit for the camizestrant combination. Those landmark results were first presented at ASCO and simultaneously published in The New England Journal of Medicine, generating considerable interest among oncologists and breast cancer specialists worldwide.
The updated analysis provides longer-term follow-up and additional evidence supporting the durability of the treatment benefit.
Significant Improvement in Progression-Free Survival
Updated data from SERENA-6 show that patients who switched to camizestrant in combination with a CDK4/6 inhibitor experienced a 55% reduction in the risk of disease progression or death compared with those who remained on an aromatase inhibitor plus a CDK4/6 inhibitor.
The results were highly statistically significant and clinically meaningful. Median progression-free survival reached 16.8 months in the camizestrant arm compared with 9.2 months in the standard-of-care arm, representing an improvement of 7.6 months.
For patients with advanced breast cancer, extending the period during which disease remains controlled is a critical treatment goal. Longer progression-free survival often translates into delayed need for additional therapies, prolonged maintenance of quality of life, and reduced exposure to the side effects associated with more aggressive treatment options.
The sustained benefit observed with camizestrant demonstrates the value of intervening early when resistance-associated ESR1 mutations emerge, rather than waiting until clinical disease progression occurs.
Durable Benefit Beyond Initial Progression
One of the most important findings from the updated analysis involved the trial’s key secondary endpoint of second progression-free survival (PFS2).
PFS2 measures the time from randomization until a second disease progression event or death after patients have moved on to subsequent therapies. This endpoint is increasingly recognized as an important indicator of long-term treatment durability because it helps determine whether the benefits of an earlier intervention continue after patients receive additional treatment lines.
The final PFS2 analysis showed that the camizestrant combination reduced the risk of second disease progression or death by 37% compared with continued aromatase inhibitor therapy.
Median PFS2 reached 25.7 months in the camizestrant arm versus 19.1 months in the comparator group.
These findings indicate that patients who switched to camizestrant continued to derive clinical benefit even after receiving later therapies. The results suggest that early intervention not only improves outcomes in the immediate treatment setting but may also positively influence the overall course of the disease.
Researchers view these data as particularly compelling because they demonstrate that the advantages gained from switching therapy are not lost after subsequent treatment transitions.
Dramatic Reductions in Circulating Tumor DNA
Another major highlight of the updated SERENA-6 results involved the profound impact of camizestrant on circulating tumor DNA levels.
Circulating tumor DNA refers to fragments of genetic material released by cancer cells into the bloodstream. Monitoring ctDNA has become an increasingly valuable tool for assessing tumor burden, tracking disease evolution, and identifying emerging resistance mechanisms.
The study showed that patients who switched to the camizestrant combination experienced rapid and substantial reductions in total ctDNA levels.
By week eight following randomization, patients receiving camizestrant achieved a median reduction of 99% in total ctDNA. In contrast, patients who remained on aromatase inhibitor therapy experienced a median 64% increase in total ctDNA during the same period.
Perhaps even more striking, 51% of patients treated with camizestrant achieved complete clearance of detectable ctDNA from their bloodstream. By comparison, only 1.9% of patients who continued standard endocrine therapy achieved total ctDNA clearance.
These findings suggest that camizestrant exerts a powerful anti-tumor effect at the molecular level and may rapidly suppress cancer activity before radiographic progression becomes evident.
Association Between ctDNA Clearance and Survival
The significance of ctDNA clearance extends beyond molecular response alone.
Previous studies across multiple cancer types have demonstrated that elimination of circulating tumor DNA during treatment is associated with improved long-term outcomes, including overall survival.
An exploratory analysis conducted within SERENA-6 further supported this relationship.
When data from both treatment arms were pooled, patients who achieved total ctDNA clearance experienced substantially better overall survival outcomes compared with those who did not clear ctDNA. The analysis revealed a 61% reduction in the risk of death among patients achieving ctDNA clearance.
These observations reinforce the growing view that ctDNA monitoring may become an increasingly important component of precision oncology strategies, helping physicians identify patients who are responding well to therapy and enabling more personalized treatment decisions.
Encouraging Overall Survival Trend
Although overall survival remains immature and the trial continues to collect additional data, interim results showed a favorable numerical trend for the camizestrant combination.
At approximately 30% data maturity, the hazard ratio for overall survival favored camizestrant, suggesting a potential survival advantage.
Investigators emphasized that additional follow-up will be required before definitive conclusions regarding overall survival can be drawn. The SERENA-6 study remains ongoing and will continue until the final overall survival analysis is completed.
Nevertheless, the favorable trend, combined with the strong progression-free survival and PFS2 findings, provides encouraging evidence that earlier intervention may ultimately translate into longer life expectancy for patients.
Delaying More Intensive Cancer Treatments
Beyond improving disease control, the camizestrant strategy also helped postpone the need for more aggressive subsequent therapies.
Additional analyses showed that patients receiving camizestrant experienced significantly longer chemotherapy- or antibody-drug conjugate (ADC)-free survival.
Median chemotherapy/ADC-free survival reached 22.6 months for patients treated with camizestrant compared with 18.7 months for those who remained on aromatase inhibitor therapy.
This finding is clinically meaningful because chemotherapy and ADC treatments, while effective, are often associated with increased toxicity and greater treatment burden. Delaying the need for these therapies can help patients maintain daily functioning and quality of life for longer periods.
The ability to extend disease control while postponing more intensive treatment represents an important objective in the management of advanced breast cancer.
Quality of Life Benefits
The updated analysis also demonstrated positive effects on patient-reported outcomes.
Patients treated with camizestrant experienced delayed deterioration in cancer-related symptoms, including pain, overall health status, and quality of life measures.
Maintaining quality of life is a critical consideration in advanced breast cancer treatment, particularly because many patients remain on therapy for extended periods. The ability to control disease while preserving physical functioning and reducing symptom burden can significantly impact patient well-being.
These findings suggest that the clinical improvements observed with camizestrant are accompanied by meaningful benefits from the patient perspective.
Expert Perspectives on the Findings
Professor François-Clément Bidard, a medical oncologist at Institut Curie and Versailles University in France and co-principal investigator of the SERENA-6 trial, emphasized the importance of intervening early in the treatment journey.
He noted that outcomes generally worsen once disease progression occurs, making it essential to optimize therapy as early as possible. According to Bidard, the updated results support a new treatment paradigm in which clinicians switch patients to a camizestrant-based regimen upon emergence of ESR1 mutations rather than waiting for progression.
Susan Galbraith, Executive Vice President of Oncology Haematology Research and Development at AstraZeneca, highlighted the remarkable ctDNA findings, noting that more than half of patients receiving camizestrant completely cleared tumor DNA from their bloodstream compared with only a small fraction of patients receiving standard care.
She stated that the results provide strong evidence of the therapy’s anti-tumor activity and support its potential to deliver long-term clinical benefits while delaying disease progression and preserving quality of life.
Regulatory Momentum Continues
The positive SERENA-6 data are already supporting regulatory progress around the world.
Camizestrant has received approval in both the United Arab Emirates and Saudi Arabia based on the trial’s findings. In Europe, the Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion recommending approval of the camizestrant combination for patients with HR-positive, HER2-negative advanced breast cancer.
Regulatory submissions are also currently under review in the United States, Japan, and several other markets. The U.S. Food and Drug Administration recently extended its review timeline to evaluate the updated SERENA-6 results, reflecting the importance of the newly reported data.
As additional overall survival data mature and regulatory reviews continue, camizestrant is increasingly emerging as a potential new standard of care for patients with ESR1-mutated HR-positive, HER2-negative advanced breast cancer. The latest SERENA-6 findings demonstrate that early molecularly guided intervention can significantly improve disease control, delay progression through multiple treatment lines, reduce tumor DNA burden, and potentially transform long-term outcomes for patients facing advanced disease.
